Severe Hepatotoxicity Secondary to Nintedanib

Jiménez, M Librero; Carrasco, C Heredia; Cano, María Carmen Fernández

doi:10.17235/reed.2020.7585/2020

Cited by 2 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In conclusion, Nintedanib demonstrated antifibrotic and anti-inflammatory activity, showing therapeutic potential in the experiment mouse model of CCL4-induced hepatic fibrosis [14] .…”

Section: Discussionmentioning

confidence: 77%

Nintedanib induced liver injury: A rare case report

Adithya S L,

Aparna Anil,

Ajima K S

et al. 2024

World J. Bio. Pharm. Health Sci.

View full text Add to dashboard Cite

Nintedanib (BIBF 1120) is a potent intracellular inhibitor of tyrosine kinase receptors, including vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors α and β, and non-receptors members of the Src family [1]. By binding competitively to the adenosine triphosphate sites of these receptors, Nintedanib blocks autophosphorylation and so inhibits the downstream intracellular signalling cascades necessary for the proliferation, migration and survival of endothelial cells, pericytes, and fibroblasts [2]. Nintedanib is approved in the European Union in combination with docetaxel for the treatment of Non- Small Cell Lung Cancer (NSCLC) of adenocarcinoma histology after first-line chemotherapy and for the treatment of Idiopathic Pulmonary Fibrosis (IPF) [3-5].We report a patient, who was admitted at Gastroenterology department with complaints of itching, yellowish discolouration of eyes, concentrated urine for 1 month & cough with shortness of breath for 3 days.He was taking treatment for Type II Diabetes Mellitus and Hypertension for past 5 & 8 years respectively. The patient also had a medical history of Interstitial Lung Disease (ILD) and was taking Cap Nintedanib for 1 month.

show abstract

“…In conclusion, Nintedanib demonstrated antifibrotic and anti-inflammatory activity, showing therapeutic potential in the experiment mouse model of CCL4-induced hepatic fibrosis [14] .…”

Section: Discussionmentioning

confidence: 77%

Nintedanib induced liver injury: A rare case report

Adithya S L,

Aparna Anil,

Ajima K S

et al. 2024

World J. Bio. Pharm. Health Sci.

View full text Add to dashboard Cite

show abstract

“… 66 The side effects, primarily diarrhea and nausea, are manageable with medication, but hepatotoxicity may occur in rare cases and the drug is not recommended for those with severe liver disease. 67 , 68 …”

Section: Current Pharmacologic Treatmentsmentioning

confidence: 99%

Idiopathic pulmonary fibrosis: Current and future treatment

Glass

Grossfeld

Renna

et al. 2022

Clinical Respiratory J

132

View full text Add to dashboard Cite

Objectives: Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease characterized by dry cough, fatigue, and progressive exertional dyspnea.Lung parenchyma and architecture is destroyed, compliance is lost, and gas exchange is compromised in this debilitating condition that leads inexorably to respiratory failure and death within 3-5 years of diagnosis. This review discusses treatment approaches to IPF in current use and those that appear promising for future development.Data Source: The data were obtained from the Randomized Controlled Trials and scientific studies published in English literature. We used search terms related to IPF, antifibrotic treatment, lung transplant, and management. Results: Etiopathogenesis of IPF is not fully understood, and treatment options are limited. Pathological features of IPF include extracellular matrix remodeling, fibroblast activation and proliferation, immune dysregulation, cell senescence, and presence of aberrant basaloid cells. The mainstay therapies are the oral

show abstract

Severe Hepatotoxicity Secondary to Nintedanib

Cited by 2 publications

References 3 publications

Nintedanib induced liver injury: A rare case report

Nintedanib induced liver injury: A rare case report

Idiopathic pulmonary fibrosis: Current and future treatment

Contact Info

Product

Resources

About